

ForPatients

by Roche

Alzheimer's Disease (AD)

CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Trial Status
Terminated

Trial Runs In
29 Countries

Trial Identifier
NCT02670083 BN29552

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose. Participants will then have the option to enter the Open Label Extension (OLE) study if eligible. Participants who do not enter the OLE study will have additional follow-up visits at 16 and 52 weeks after the last dose, primarily for safety and also for limited efficacy assessments.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02670083 BN29552
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=50 Years & <= 85 Years

Healthy Volunteers
No
